Shift From Adalimumab Originator to Biosimilars in Denmark

被引：58
|
作者：
Jensen, Thomas Bo [1 ]
Kim, Seoyoung C. [2 ]
Jimenez-Solem, Espen [1 ]
Bartels, Dorthe [3 ]
Christensen, Hanne Rolighed [1 ]
Andersen, Jon Traerup [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg, Dept Clin Pharmacol, Bispebjerg Bakke 23,Entrance 20C,2nd Floor, DK-2400 Copenhagen NV, Denmark
[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[3] Amgros, Copenhagen, Denmark
来源：
JAMA INTERNAL MEDICINE | 2020年 / 180卷 / 06期
关键词：
D O I：
10.1001/jamainternmed.2020.0338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：902 / 903
页数：2
相关论文
共 50 条
  • [21] Adalimumab originator versus biosimilar adalimumab
    Anderson, E.
    Waller, K.
    Chetwood, J.
    Tamilarasan, A. G.
    Paramsothy, S.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 136 - 136
  • [22] Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study
    Lontai, Livia
    Gonczi, Lorant
    Balogh, Fruzsina
    Komlodi, Nora
    Resal, Tamas
    Farkas, Klaudia
    Molnar, Tamas
    Miheller, Pal
    Golovics, Petra A.
    Schafer, Eszter
    Szamosi, Tamas
    Ilias, Akos
    Lakatos, Peter L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (12) : 1639 - 1645
  • [23] Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
    Larid, Guillaume
    Baudens, Guy
    Dandurand, Alexis
    Coquerelle, Pascal
    Goeb, Vincent
    Guyot, Marie Helene
    Marguerie, Laurent
    Maury, Frederic
    Veillard, Eric
    Houvenagel, Eric
    Salmon, Jean-Hugues
    Flipo, Rene-Marc
    Gervais, Elisabeth
    FRONTIERS IN MEDICINE, 2022, 9
  • [24] Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
    Larid, Guillaume
    Baudens, Guy
    Dandurand, Alexis
    Coquerelle, Pascal
    Goeb, Vincent
    Guyot, Marie-Helene
    Marguerie, Laurent
    Maury, Frederic
    Eric, Viellard
    Houvenagel, Eric
    Salmon, Jean Hugues
    Flipo, Rene-Marc
    Gervais, Elisabeth
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2064 - 2067
  • [25] The effectiveness of adalimumab biosimilars and originator for the treatment of psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
    Phan, Duc Binh
    Bewley, Anthony
    Laws, Philip
    Mackenzie, Teena
    Smith, Catherine
    Griffiths, Christopher
    Lunt, Mark
    Warren, Richard B.
    Yiu, Zenas Z. N.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I1 - I2
  • [26] Safety evaluation of infliximab originator and biosimilars
    Reactions Weekly, 2018, 1727 (1) : 11 - 11
  • [27] Adalimumab and the Challenges for Biosimilars
    Gellad, Walid F.
    Good, Chester B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (22): : 2171 - 2172
  • [28] Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
    Tarsi, Antonio
    Mocci, Giammarco
    Cuomo, Antonio
    Ferronato, Antonio
    Elisei, Walter
    Picchio, Marcello
    Maconi, Giovanni
    Scaldaferri, Franco
    Papa, Alfredo
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (04) : 411 - 416
  • [29] WAR RAGES BETWEEN INFLIXIMAB BIOSIMILARS AND THEIR ORIGINATOR
    Loubiere, A.
    Bocquet, F.
    Paubel, P.
    VALUE IN HEALTH, 2016, 19 (07) : A597 - A597
  • [30] A PHARMACEUTICAL GUIDE TO ADALIMUMAB BIOSIMILARS
    Almaaytah, Ammar
    FARMACIA, 2022, 70 (03) : 379 - 385
12345